• Meta-Analysis •

Different concentrations of hyaluronic acid eye drops for dry eye syndrome: a systematic review and Meta-analysis

Xiao-Wei Ouyang¹, Sheng Fang², Yun-Min Yi³, Shi-Peng Zou⁴, Qi-Yu Hu¹, Zi-Xuan Huang¹, Qing-Xia Li¹, Jin-Yan Luo¹

¹Department of Ophthalmology, Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang 330000, Jiangxi Province, China

²Department of Ophthalmology, Jiangxi Hospital of Integrated Traditional Chinese and Western Medicine, Nanchang 330000, Jiangxi Province, China

³Department of Cataract, Nanchang University Affiliated Eye Hospital, Nanchang 330000, Jiangxi Province, China

⁴Department of Neuro-ophthalmology, Nanchang University Affiliated Eye Hospital, Nanchang 330000, Jiangxi Province, China

Correspondence to: Jin-Yan Luo. Nanchang Hongdu Hospital of Traditional Chinese Medicine, Nanchang 330000, Jiangxi Province, China. 804639947@qq.com

Received: 2023-09-23 Accepted: 2024-02-02

Abstract

• **AIM:** To compare high or low concentration of hyaluronic acid eye drops (HY) for dry eye syndromes (DES).

• **METHODS:** Randomized controlled trials (RCTs) comparing various concentrations of HY were searched in PubMed, Embase, Web of Science, Cochrane, SinoMed, CNKI, Wanfang Database, CQVIP, and Chinese journals databases between inception and July 2023. Pooled standardized mean differences (SMD) or weighted mean difference (WMD) with 95% confidence intervals (CI) from RCTs evaluating Schirmer's I test (SIT), corneal fluorescein staining score (CFS), tear breakup time (TBUT), DES score (DESS), and Ocular Surface Disease Index (OSDI) were calculated. Sensitivity analysis, Egger's test and Metaregression analysis were performed for all indicators.

• **RESULTS:** We conducted a Meta-analysis of 10 RCTs that met the inclusion criteria, involving 1796 cases. High-concentrations group significantly improved the outcome of CFS according to random effects modelling (SMD, -3.37; 95%CI, -5.25 to -1.48; *P*=0.0005). The rest of the results were not statistically significant, including indicators such as SIT, TBUT, DESS and OSDI.

• **CONCLUSION:** For dry eyes with positive corneal staining, a high concentration of HY is recommended,

whereas in other cases, a high concentration of HY does not offer a more pronounced advantage over a low concentration of HY in the treatment of dry eyes.

• **KEYWORDS:** dry eye; hyaluronic acid; concentration; Meta-analysis

DOI:10.18240/ijo.2024.06.17

Citation: Ouyang XW, Fang S, Yi YM, Zou SP, Hu QY, Huang ZX, Li QX, Luo JY. Different concentrations of hyaluronic acid eye drops for dry eye syndrome: a systematic review and Meta-analysis. *Int J Ophthalmol* 2024;17(6):1110-1119

INTRODUCTION

D ry eye syndrome (DES) is a complex ocular surface disease that involves multiple factors. According to the International Dry Eye Workshop, dry eye is characterized by an imbalance in the tear film and ocular symptoms. However, due to reduced corneal sensitivity, such patients may also have tear abnormalities without symptoms. The various factors contributing to the development of dry eye often overlap and interact, including tear-film instability, hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities^[1]. Additionally, dry eyes can harm visual function and quality of life and impose a significant economic burden^[2-3].

Various factors can contribute to the development of dry eye. Certain diseases, such as diabetes, can lead to damage in the microvasculature of the lacrimal gland, autonomic neuropathy, and diabetic sensory neuropathy of the cornea, all of which can impact the quality and quantity of tears^[4]. Additionally, chronic graft-versus-host disease accompanied by conjunctival inflammation and fibrosis^[5], as well as autoimmune diseases like rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's syndrome, can also contribute to dry eye^[6]. Furthermore, impairment of the neural feedback loop responsible for regulating tear secretion can worsen the symptoms of ocular surface disease^[7]. Obstructive meibomiangland dysfunction can alter the lipid composition of tears^[8], while conjunctival achalasia and eyelid laxity (floppy eyelid syndrome) may also contribute to the development of dry eye^[9]. Certain medications, such as furosemide, propranolol, candesartan, cetirizine, and ranitidine, have been known to trigger dry eye^[10]. Some topical ocular medications contain preservatives, such as benzalkonium chloride, that can cause or worsen dry eye symptoms and signs^[11]. It is imperative to remain cognizant of other potential instigators for dry eyes, such as ocular-surface inflammation caused by ocular disease, infection, or immune-mediated conditions, as well as environmental exposures such as wind and airborne particulates^[12]. Moreover, sex hormones can exert an impact on the surface of the eye by modifying goblet-cell density and the production and quality of tears^[13]. Any ailment or circumstance that diminishes the blink rate can intensify the likelihood of dry eye by inducing tear evaporation, such as Parkinson's disease or prolonged screen viewing^[14-16].

To effectively manage DES, several therapeutic strategies can be employed. These strategies include reducing inflammation, modifying one's diet and lifestyle choices, and treating any associated eyelid conditions. In addition, the use of artificial tear formulations of different viscosities and compositions^[17], topical lubricants in the form of gels or ointments, diquafosol tetrasodium ophthalmic solution, and autologous serums can all improve DES. Among these formulations, sodium hyaluronate is a frequently utilized artificial tear that can increase retention time and improve ocular surface hydration and lubrication, ameliorating DES. Clinical trials have demonstrated the efficacy of sodium hyaluronate eye drops as a viable treatment option for DES^[18]. With the earliest clinical trials dating back to 1986^[19], hyaluronic acid eye drops (HY) can be considered an "old hero" in the fight against dry eye disease. Previous Meta-analyses have demonstrated that preparations containing HY improve Schirmer's I test (SIT) more than non-HY preparations and less improvement in tear breakup time (TBUT)^[20]. However, no literature compares explicitly the effects of HY concentration.

Currently, the concentration of HY ranges from 0.1% to 0.4%, and most clinical trials have shown that the higher the concentration of HY, the more effective it is. This Metaanalysis aimed to compare the efficacy of high-concentration HY versus low-concentration HY preparations in the treatment of DES and to determine whether there is an advantage to increasing the concentration from an evidence-based perspective. No evidence-based research articles were found at the time of closing this article. In addition, this paper was registered with PROSPERO under registration number CRD42023453696.

MATERIALS AND METHODS

Search Strategy Our research team has conducted a comprehensive search of English and Chinese language databases, utilizing a variety of search terms on "Hyaluronic

Acid" and "Dry Eye Syndromes". We have thoroughly examined PubMed, Embase, Web of Science, and the Cochrane Database, as well as SinoMed, CNKI, Wanfang Database, CQVIP, and Chinese Med journals. Our search has encompassed all pertinent publications from inception to July 2023 without imposing any language restrictions.

Selection Criteria Our review adhered to the PRISMA guidelines and utilized a predetermined protocol. Our inclusion criteria consisted solely of randomized controlled trials (RCTs) conducted on human subjects, focusing on comparing the efficacy of various concentrations of hyaluronic acid. In cases where additional interventions were administered (*e.g.*, tobramycin dexamethasone eye drops), all groups had to be identical. Two authors (Ouyang XW, Fang S) independently confirmed the eligibility of the studies and collated the data from the qualifying studies. Data extracted by Ouyang XW and Fang S, both sides check each other out, and the senior author (Yi YM) is responsible for resolving discrepancies. This article does not discuss any ethical concerns.

Statistical Analysis The Meta-analyses were performed using Revman 5.4 and Stata17 Software. Standardised mean difference (SMD) or weighted mean difference (WMD) was used for continuous variables, and 95% confidence intervals (CI) were used to calculate pooled estimates. A statistically significant *P*-value was considered to be less than 0.05. Heterogeneity between trials was measured using I^2 values, with I^2 values greater than 50% indicating significant heterogeneity. The random effects model analyzed all the results, and sensitivity analysis and Meta-regression methods were used for the included results. Finally, Egger's test was used to determine publication bias, and trim and fill analysis were employed if publication bias was detected.

RESULTS

Literature Search Results The initial literature search identified a total of 6039 articles. Following the removal of 2502 duplicates, 3527 articles were excluded based on the inclusion criteria. The remaining ten studies were retrieved successfully and were incorporated in the Meta-analysis. Of these, 8 RCTs reported TBUT results^[21-28]. It is important to note that since TBUT was the sum of three times in the study of Calonge *et al*^[21], we did not include this literature, and since</sup>mild and severe phenotypes were compared in the study of Zheng and Zhao^[28], we collected two sets of data from this study. Three RCTs^[21,24,28] reported Ocular Surface Disease Index (OSDI) results, and two sets of data were reported by type in the Zheng and Zhao's study^[28]. Four RCTs^[21,23,25-26] reported SIT results, while 4 RCTs^[22-23,26,29] reported DES score (DESS) results. Five RCTs^[22-24,26,30] reported corneal fluorescein staining score (CFS) results. Figure 1 summarizes the study selection process.




Figure 1 Selection process for the study.

Characteristics of Studies This review encompasses ten studies conducted between 2014 and 2023, which investigate the effects of various interventions on individuals with DES. The study population is diverse, including postoperative cataract surgery, laser *in situ* keratomileus surgery (LASIK), and non-surgical cases. Study participants exhibit varying degrees of severity of DES and are followed up for a period ranging from 4 to 12wk. The concentration of HY administered across these studies ranges from 0.1% to 0.3%. In addition, 5 of the articles include other interventions, such as antiphlogosis eye drops, and these interventions are consistent across all groups. Table 1 provides a summary of crucial study characteristics.

Risk of Bias Assessment Figure 2 shows the results of the risk of bias assessment for the 10 RCTs for which Meta-analysis was subsequently performed. Among the 10 studies, 6 RCTs reported appropriate random sequence generation, and 7 RCTs did not detail allocation concealment or blinding methods. No biases related to attrition or other aspects were detected in any of the studies. One RCT found a high risk of selection bias, and another identified a high risk of reporting bias. All studies featured in the Meta-analysis underwent assessment of potential bias employing the Cochrane Risk of Bias tool^[31].

Meta-Analysis Results

Baseline data Upon analysis of the baseline data of age, SIT, TBUT, DESS, CFS, and OSDI, it observes that none

Table	Table 1 Summary of crucial study characteristics	ucial study	characteristi	ics										
No.	Study	Location	Period	Population	Age, (mean+SD, γ)	Follow up duration	Severity of DES of subject	Concentration of HY	Other interventions ^b	SIT	TBUT	DESS	CFS	OSDI
1	Calonge <i>et al</i> ^[21]	Spain	2023	Non-surgical	55.7±12.4	5-12wk	Moderate to severe	$0.18\% \text{ vs } 0.3\%^{a}$	None	Yes	Yes	No	No	Yes
2	Hong and Chen ^[22]	China	2014-2015	Postoperative cataract surgery	51-78 (range)	4wk	Unspecified	0.1% vs 0.3%	Tobradex+pranopulin	No	Yes	Yes	Yes	No
ŝ	Jin and Dang ^[23]	China	2015-2016	Postoperative cataract surgery	68.63±5.93	1mo	Unspecified	0.1% vs 0.3%	Tobradex+pranopulin	Yes	Yes	Yes	Yes	No
4	Jun <i>et al</i> ^[24]	Korean	2022	Non-surgical	46.1±14.3	4-8wk	Moderate to severe	0.15% vs 0.3%	None	No	Yes	No	Yes	Yes
ß	Ntonti <i>et al</i> ^[25]	Greece	2017-2018	Postoperative cataract surgery	72.4±8.7	4-6wk	Non-DES	0.1% vs 0.3%	Tobradex	Yes	Yes	No	No	No
9	Song ^[26]	China	2016-2017	Postoperative cataract surgery	66.12±1.14	1mo	Unspecified	0.1% vs 0.3%	Tobradex+pranopulin	Yes	Yes	Yes	Yes	No
7	Yin and Kong ^[27]	China	2020-2021	Post-LASIK	25.11±1.21	1mo	Unspecified	0.1% vs 0.3%	None	No	Yes	No	No	No
∞	Zheng and Zhao ^[28]	China	2016-2017	Post-LASIK	24.1±5.0	1-3mo	Mild and severe	0.1% vs 0.3%	None	No	Yes^d	No	No	Yes ^d
6	Jing ^[29]	China	2018	Postoperative cataract surgery	64.57±4.35	1mo	Unspecified	0.1% vs 0.3%	Tobradex+pranopulin	No	No	Yes	No	No
10	Yang ^[30]	China	2017	Postoperative cataract surgery	56±4.6	1mo	Unspecified	0.1% vs 0.3%	None	No	No	No	Yes	No
HX: H	yaluronic acid eye	drops; SIT	: Schirmer's	HY: Hyaluronic acid eye drops; SIT: Schirmer's I test; TBUT: Tear break-up time; DESS: Dry eye symptom score; CFS: Corneal fluorescein staining score; OSDI: Ocular Surface Disease Index; LASIK: Laser in	e; DESS: Dry eye	symptom scc	re; CFS: Corneal fluo	rescein staining	score; OSDI: Ocular Su	urface D	Jisease	Index; L	ASIK: L	aser <i>in</i>
situ ke	eratomileus surge	ry; DES: Dr	'y eye syndro	situ keratomileus surgery; DES: Dry eye syndrome; Tobradex: Tobramycin dexamethasone eye drops. ^a Hyaluronic acid 0.30% ocular gel; ^b Drugs were the same in each group in the single study; ^c Sum of 3	amethasone eye	drops. ^a Hyalu	Ironic acid 0.30% ocu	lar gel; ^b Drugs w	vere the same in each	group i	n the si	ngle stu	idy; ^c Su	m of 3
meast	measurements; ^d Two groups of cases were collected.	oups of ca	ses were coll	lected.										




Figure 2 The results of the risk of bias assessment.

of the outcomes were statistically significant. In addition, in the analysis of heterogeneity, the value of age was 53%, and the rest of the results were less than 50%, with little overall heterogeneity (Figure 3).

Schirmer's I Test Based on the analysis conducted through random-effects modeling, there was no significant improvement in SIT outcome within the high-concentration group compared to those using low-concentration preparations. The WMD was calculated to be 0.57, with a 95%CI of -0.15 to 1.29, and the data did not achieve statistical significance (P=0.12). There was significant overall heterogeneity with an I^2 value of 80%. Moreover, Egger's test did not indicate publication bias (P=0.795; Figure 4).

Tear Breakup Time The analysis shows no substantial variation in the TBUT outcome between the highconcentration group and the low-concentration group. The random-effects modeling showed the WMD was calculated to be 0.98, with a 95%CI of -1.09 to 3.04, and the results did not reach statistical significance (P=0.35). There was significant overall heterogeneity with an I^2 value of 98%. Egger's test demonstrated significant asymmetry (P=0.045), while the trim and fill analysis did not have any impact on the results, indicating stable TBUT outcomes (Figure 5).

Dry Eye Symptoms Score The results of the analysis using random-effects modeling indicate that the high-concentration group did not demonstrate any significant improvement in

DESS outcome when compared to the low-concentration preparations. The SMD was calculated to be -1.50 with a 95%CI ranging from -3.20 to 0.19, and the results did not reach statistical significance (P=0.08), the overall heterogeneity was found to be significant (I^2 =98%). Egger's regression test analysis revealed no evidence of publication bias (P=0.148; Figure 6).

Corneal Fluorescein Staining Score Random-effects modeling demonstrated that individuals in the high-concentration group experienced a notable improvement in CFS outcome compared to those utilizing low-concentration preparations. The SMD was determined to be -3.37 with a 95%CI of -5.52 to -1.48, and the results were statistically significant (*P*=0.0005), the significant overall heterogeneity with an I^2 value of 98%. Egger's regression test showed significant asymmetry with statistical significance (*P*=0.000). However, after implementing the trim and fill method, it was determined that the combined results did not change direction. The *P* value before and after cutting and filling was 0, indicating robust results (Figure 7).

Ocular Surface Disease Index The analysis results reveal that there is no significant variation in OSDI outcome between high-concentration and low-concentration groups as per the random-effects model. The SMD stands at -0.24 with a 95%CI of -0.75 to 0.27 and the results did not attain statistical significance (P=0.36). The overall heterogeneity was significant, with a value of 64%. Moreover, Egger's regression

AGE			ncentrati	on	Low co	ncentrati	on		Mean Difference	Mean Difference
Study or Subgroup	N	lean	SD	Total	Mean	SD	Total	Weight		IV. Random, 95% Cl
Calonge 2023		55.7	12.4	35	57.8	10.9	35	1.8%	-2.10 [-7.57, 3.37]	·
Jin 2018	6	8.63	5.93	28	68.95	5.98	28	5.0%	-0.32 [-3.44, 2.80]	
Jing 2019		4.57	4.35	56	64.93	4.26	56	13.4%		
Jun 2022		46.1	14.3	25	44.1	12.1	27	1.1%	2.00 [-5.23, 9.23]	
Ntonti 2019		72.4	8.7	90	72.9	7.8	90	7.6%		
Song 2018	6	6.12	1.14	45	66.21	1.24	45	29.2%	-0.09 [-0.58, 0.40]	- -
Yang 2019		56	4.6	25	52	5.5	25	5.9%	4.00 [1.19, 6.81]	
Yin 2022	2	5.11	1.21	50	24.17	1.12	50	29.7%	0.94 [0.48, 1.40]	-
Zheng 2018 (Mild type)	•	22.7	4.7	15	24.3	6.8	15	3.0%		
Zheng 2018 (Severe typ	pe)	25.2	3.7	15	24.3	6.8	15	3.3%	0.90 [-3.02, 4.82]	
										-
Total (95% CI)				384			386	100.0%	0.35 [-0.40, 1.11]	· · · · · · · · · · · · · · · · · · ·
Heterogeneity: Tau ² = 0.4			f = 9 (P :	= 0.03);	I ² = 539	6				-4 -2 0 2 4
Test for overall effect: Z =	= 0.92 (P :	= 0.36)								Favours [High concentration] Favours [Low concentration]
										Tarours (riigh concentration) Tarours (concentration)
SIT	High co	oncentra	ation	Low	concen	tration		N	lean Difference	Mean Difference
Study or Subgroup	Mean	SD	Total	Mear	n S	D Tota	We	iaht l'	V. Random, 95% CI	IV. Random, 95% CI
Calonge 2023	11.3	9.6	35	12.3				.1%	-1.00 [-5.89, 3.89]	
Jin 2018	11.37	1	28	11.1				.0%	0.23 [-0.26, 0.72]	
Ntonti 2019	11.93	3.6	90	11.6	4 3.4	3 90	2	.5%	0.29 [-0.74, 1.32]	
Song 2018	8.1	0.21	45	8.0	5 0.5	6 45	86	.3%	0.05 [-0.12, 0.22]	
										Т
Total (95% CI)			198			198	100	0%	0.07 [-0.09, 0.24]	4
							100	.076	0.07 [-0.09, 0.24]	
Heterogeneity: Tau ² = 0				= 0.84	i); l² = 0	%			-	-4 -2 0 2 4
Test for overall effect: Z	Z = 0.90 (F	P = 0.37)							Favours [High concentration] Favours [Low concentration]
										Favours [riigii concentration] Favours [Low concentration]
TRUT		ligh con	centrati	on		ncentrati	n		Mean Difference	Mean Difference
								Weight		
Study or Subgroup		lean			Mean					IV. Random. 95% Cl
Hong 2016		3.22	1.23	29	3.16	1.32	29	2.2%	0.06 [-0.60, 0.72]	
Jin 2018	1	0.96	1.13	28	11.27	1.07	28	2.9%	-0.31 [-0.89, 0.27]	
Jun 2022		5.2	2.1	25	4.5	2	27	0.8%	0.70 [-0.42, 1.82]	
Ntonti 2019	1	1.92	6.92	90	11.51	7.08	90	0.2%		
Song 2018		4.9	0.19	45	4.92	0.29	45	93.5%		· · · · · · · · · · · · · · · · · · ·
									-0.02 [-0.12, 0.08]	
Yin 2022		1.31	5.01	50	11.72	4.71	50	0.3%		
Zheng 2018 (Mild type)	1	4.41	5.04	15	13.87	5.5	15	0.1%	0.54 [-3.24, 4.32]	· · · · · · · · · · · · · · · · · · ·
Zheng 2018 (Severe typ	pe) 1	2.18	3.7	15	13.89	7.03	15	0.1%	-1.71 [-5.73, 2.31]	· · · · · · · · · · · · · · · · · · ·
Total (95% CI)				297			299	100.0%	-0.02 [-0.12, 0.08]	•
							200	100.074	-0.02 [-0.12, 0.00]	
Heterogeneity: Tau ² = 0.0			= 7 (P =	0.81); I	* = 0%					-2 -1 0 1 2
Test for overall effect: Z =	= 0.43 (P :	= 0.66)								Favours [High concentration] Favours [Low concentration]
										r avoars (righ concentration) - Lavours (now concentration)
DESS	High co	ncentra	ation	Low	concent	ration		Std	Mean Difference	Std. Mean Difference
Study or Subgroup										
Hong 2016	Mean	SD	Total		s		Wei	aht l		IV. Random, 95% CI
	Mean	SD	Total	Mean) Total	Wei		V. Random, 95% Cl	IV. Random. 95% Cl
	5.63	0.68	Total 29	Mean 5.76	0.62	<u>7 Total</u> 2 29	18.	3%	V. Random, 95% Cl -0.20 [-0.71, 0.32]	IV. Random. 95% Cl
Jin 2018	5.63 0.64	0.68 0.56	<u>Total</u> 29 28	Mean 5.76 0.64	0.62	<u>7 Total</u> 2 29 7 28	18. 17.	3% 8%	V. Random, 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52]	IV. Random. 95% Cl
Jin 2018	5.63	0.68	Total 29	Mean 5.76	0.62	<u>7 Total</u> 2 29 7 28	18.	3% 8%	V. Random, 95% Cl -0.20 [-0.71, 0.32]	IV. Random. 95% Cl
Jin 2018 Jing 2019	5.63 0.64 5.65	0.68 0.56 0.63	Total 29 28 56	Mean 5.76 0.64 5.74	0.62 0.57 0.61	<u>7 Total</u> 2 29 7 28 1 56	18. 17. 35.	3% 8% 4%	V. Random. 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23]	IV. Random. 95% Cl
Jin 2018 Jing 2019	5.63 0.64	0.68 0.56	<u>Total</u> 29 28	Mean 5.76 0.64	0.62 0.57 0.61	<u>7 Total</u> 2 29 7 28 1 56	18. 17.	3% 8% 4%	V. Random, 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52]	IV. Random. 95% Cl
Jin 2018 Jing 2019 Song 2018	5.63 0.64 5.65	0.68 0.56 0.63	Total 29 28 56 45	Mean 5.76 0.64 5.74	0.62 0.57 0.61	2 29 7 28 1 56 2 45	18. 17. 35. 28.	3% 8% 4% 5%	V. Random, 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38]	IV. Random. 95% Cl
Jin 2018 Jing 2019 Song 2018 Total (95% CI)	5.63 0.64 5.65 5.15	0.68 0.56 0.63 0.21	Total 29 28 56 45 158	Mean 5.76 0.64 5.74 5.16	0.62 0.51 0.61 0.32	2 Total 2 29 7 28 1 56 2 45 158	18. 17. 35.	3% 8% 4% 5%	V. Random. 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23]	IV. Random. 95% Cl
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0	5.63 0.64 5.65 5.15	0.68 0.56 0.63 0.21	Total 29 28 56 45 158 df = 3 (P	Mean 5.76 0.64 5.74 5.16	0.62 0.51 0.61 0.32	2 Total 2 29 7 28 1 56 2 45 158	18. 17. 35. 28.	3% 8% 4% 5%	V. Random, 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38]	
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0	5.63 0.64 5.65 5.15	0.68 0.56 0.63 0.21	Total 29 28 56 45 158 df = 3 (P	Mean 5.76 0.64 5.74 5.16	0.62 0.51 0.61 0.32	2 Total 2 29 7 28 1 56 2 45 158	18. 17. 35. 28.	3% 8% 4% 5%	V. Random, 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38]	
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0	5.63 0.64 5.65 5.15	0.68 0.56 0.63 0.21	Total 29 28 56 45 158 df = 3 (P	Mean 5.76 0.64 5.74 5.16	0.62 0.51 0.61 0.32	2 Total 2 29 7 28 1 56 2 45 158	18. 17. 35. 28.	3% 8% 4% 5%	V. Random, 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38]	
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z	5.63 0.64 5.65 5.15 0.00; Chi ² 2 = 0.87 (F	0.68 0.56 0.63 0.21 = 0.42, o P = 0.39)	Total 29 28 56 45 158 df = 3 (P	Mean 5.76 0.64 5.74 5.16 = 0.94	0.62 0.57 0.61 0.32	D Total 2 29 7 28 1 56 2 45 2 45 158	18. 17. 35. 28.	3% 8% 4% 5% 0%	V. Random. 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12]	-1 -0.5 0 0.5 1 Fevours (High concentration) Favours (Low concentration)
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS	5.63 0.64 5.65 5.15 0.00; Chi ² = 0.87 (F High co	0.68 0.56 0.63 0.21 = 0.42, o = 0.39)	Total 29 28 56 45 158 df = 3 (P	Mean 5.76 0.64 5.74 5.16 = 0.94	0.62 0.57 0.61 0.32); I ² = 0%	D Total 2 29 7 28 1 56 2 45 158 6 ration	18. 17. 35. 28. 100.	3% 8% 4% 5% 0% Std	V. Random. 95% Cl -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] -0.10 [-0.32, 0.12]	Favours [Lew concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup	5.63 0.64 5.65 5.15 0.00; Chi ² = 0.87 (F High co Mean	0.68 0.56 0.63 0.21 = 0.42, o = 0.39)	Total 29 28 56 45 158 df = 3 (P) attion Total	Mean 5.76 0.64 5.74 5.16 = 0.94	0.62 0.57 0.61 0.32); I ² = 0%	Total 2 29 7 28 1 56 2 45 158 6 ration 0 Total	18. 17. 35. 28. 100.	3% 8% 4% 5% 0% Std. ght ľ	V. Random. 95% Cl -0.20 (-0.71, 0.32) 0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] - Mean Difference V. Random. 95% Cl	-1 -0.5 0 0.5 1 Fevours (High concentration) Favours (Low concentration)
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Zalonge 2023	5.63 0.64 5.65 5.15 0.00; Chi ² = 0.87 (P High co <u>Mean</u> 5.37	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) encentra SD 1.29	Total 29 28 56 45 158 df = 3 (P) attion Total 35	Mean 5.76 0.64 5.74 5.16 = 0.94 Low Mean 5.49	i 0.62 0.57 0.61 i 0.32 i 0.32 i; l ² = 09 concent <u>SI</u> 0 1.17	Total 2 29 7 28 1 56 2 45 158 6 7 28 7 35	18. 17. 35. 28. 100. <u>Weit</u> 18.	3% 8% 4% 5% 0% <u>Std</u> <u>aht ľ</u> 7%	V. Random. 95% Cl -0.20 [-0.71, 0.32] -0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] - Mean Difference V. Random. 95% Cl -0.10 [-0.57, 0.37]	Favours [Lew concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016	5.63 0.64 5.65 5.15 0.00; Chi ² : 2 = 0.87 (P High co Mean 5.37 4.97	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) = 0.39) = 0.98	Total 29 28 56 45 158 df = 3 (P) ntion Total 35 29	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 0 Mean 5.49 5.03	i 0.62 0.57 0.61 0.32); I ² = 0% concent <u>SI</u> 1.17 1.12	Total 2 29 7 28 1 56 2 45 158 6 7 25 7 35 2 29	18. 17. 35. 28. 100. <u>Weik</u> 18. 15.	3% 8% 4% 5% 0% <u>std.</u> 7% 5%	V. Random. 95% Cl -0.20 (-0.71, 0.32) -0.00 (-0.52, 0.52) -0.14 (-0.52, 0.23) -0.04 (-0.45, 0.38) -0.10 (-0.32, 0.12) -0.10 (-0.32, 0.12) -0.00 (-0.57, 0.37) -0.06 (-0.57, 0.46)	Favours [Lew concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016	5.63 0.64 5.65 5.15 0.00; Chi ² = 0.87 (P High co <u>Mean</u> 5.37	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) encentra SD 1.29	Total 29 28 56 45 158 df = 3 (P) attion Total 35	Mean 5.76 0.64 5.74 5.16 = 0.94 Low Mean 5.49	i 0.62 0.57 0.61 0.32); I ² = 0% concent <u>SI</u> 1.17 1.12	Total 2 29 7 28 1 56 2 45 158 6 7 25 7 35 2 29	18. 17. 35. 28. 100. <u>Weit</u> 18.	3% 8% 4% 5% 0% <u>std.</u> 7% 5%	V. Random. 95% Cl -0.20 [-0.71, 0.32] -0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] - Mean Difference V. Random. 95% Cl -0.10 [-0.57, 0.37]	Favours [Lew concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018	5.63 0.64 5.65 5.15 0.00; Chi ² : 2 = 0.87 (P High co Mean 5.37 4.97	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) = 0.39) = 0.98	Total 29 28 56 45 158 df = 3 (P) ntion Total 35 29	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 0 Mean 5.49 5.03	i 0.62 0.57 0.61 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32	Total 2 29 7 28 1 56 2 45 158 158 6 7 7 35 2 29 5 28	18. 17. 35. 28. 100. <u>Weik</u> 18. 15.	3% 8% 4% 5% 0% <u>std</u> 7% 5% 0%	V. Random. 95% Cl -0.20 (-0.71, 0.32) -0.00 (-0.52, 0.52) -0.14 (-0.52, 0.23) -0.04 (-0.45, 0.38) -0.10 (-0.32, 0.12) -0.10 (-0.32, 0.12) -0.00 (-0.57, 0.37) -0.06 (-0.57, 0.46)	Favours [Lew concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018 Jun 2022	5.63 0.64 5.65 5.15 0.00; Chi ² : 2 = 0.87 (P High co <u>Mean</u> 5.37 4.97 0.61 2.1	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra 5D 1.29 0.98 0.57 1.3	Total 29 28 56 45 158 df = 3 (P) ntion Total 35 29 28 25	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 6 Mean 5.49 5.03 0.61 3.2	; I ² = 0% ; I ² = 0%	Total 2 29 7 28 1 56 2 45 158 158 6 7 7 35 2 29 5 28 4 27	18. 17. 35. 28. 100. 100. <u>Weis</u> 18. 15. 15. 15.	3% 8% 4% 5% 0% <u>Std</u> 7% 5% 0% 4%	V. Random. 95% CI. -0.20 [-0.71, 0.32] -0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] -0.10 [-0.32, 0.12] -0.10 [-0.57, 0.37] -0.10 [-0.57, 0.48] 0.05 [-0.57, 0.57] 0.05 [-0.57, 0.57]	Favours [Lew concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018 Jun 2022 Song 2018	5.63 0.64 5.65 5.15 0.00; Chi ² : = 0.87 (F High co <u>Mean</u> 5.37 4.97 0.61 2.1 5.82	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra SD 1.29 0.98 0.57 1.3 0.19	Total 29 28 56 45 158 df = 3 (P) ntion Total 35 29 28 25 45	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 0 Mean 5.49 5.03 0.61 3.2 5.8	i 0.62 0.55 0.61 0.32 0.32 0.32 0.51 0.32 0.52 0.11 0.52 0.11 0.52 0.12 0.53 0.12 0.53 0.12 0.53 0.12 0.12 0.15 0.55 0.55 0.55 0.55 0.55 0.55 0.55	Total 2 29 7 28 1 56 2 45 158 158 6 7 7 35 2 29 5 28 4 27 5 45	18. 17. 28. 100. Weik 18. 15. 15. 13. 24.	3% 8% 4% 5% 0% <u>Std</u> 7% 5% 0% 4%	V. Random. 95% C1 -0.20 [-0.71, 0.32] -0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] -0.10 [-0.32, 0.12] -0.10 [-0.57, 0.47] -0.06 [-0.57, 0.47] -0.00 [-0.57, 0.47] -0.00 [-0.52, 0.52] -0.00 [-0.52, 0.52] -0.56 [-1.11, 0.00] -0.12 [-0.30, 0.53]	Favours [Lew concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018 Jun 2022 Song 2018	5.63 0.64 5.65 5.15 0.00; Chi ² : 2 = 0.87 (P High co <u>Mean</u> 5.37 4.97 0.61 2.1	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra 5D 1.29 0.98 0.57 1.3	Total 29 28 56 45 158 df = 3 (P) ntion Total 35 29 28 25	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 6 Mean 5.49 5.03 0.61 3.2	i 0.62 0.55 0.61 0.32 0.32 0.32 0.51 0.32 0.52 0.32 0.11 0.52 0.11 0.52 0.12 0.53 0.12 0.53 0.12 0.12 0.15 0.55 0.55 0.55 0.55 0.55 0.55 0.55	Total 2 29 7 28 1 56 2 45 158 158 6 7 7 35 2 29 5 28 4 27 5 45	18. 17. 35. 28. 100. 100. <u>Weis</u> 18. 15. 15. 15.	3% 8% 4% 5% 0% <u>Std</u> 7% 5% 0% 4%	V. Random. 95% CI. -0.20 [-0.71, 0.32] -0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] -0.10 [-0.32, 0.12] -0.10 [-0.57, 0.37] -0.10 [-0.57, 0.48] 0.05 [-0.57, 0.57] 0.05 [-0.57, 0.57]	Favours [Mgh concentration] Stut. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS <u>Study or Subgroup</u> Calonge 2023 Hong 2016 Jin 2018 Jun 2018 Jun 2022 Song 2018 Yang 2019	5.63 0.64 5.65 5.15 0.00; Chi ² : = 0.87 (F High co <u>Mean</u> 5.37 4.97 0.61 2.1 5.82	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra SD 1.29 0.98 0.57 1.3 0.19	Total 29 28 56 45 158 df = 3 (P) ation Total 29 28 25 45 25	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 0 Mean 5.49 5.03 0.61 3.2 5.8	i 0.62 0.55 0.61 0.32 0.32 0.32 0.51 0.32 0.52 0.32 0.11 0.52 0.11 0.52 0.12 0.53 0.12 0.53 0.12 0.12 0.15 0.55 0.55 0.55 0.55 0.55 0.55 0.55	Total 2 29 7 28 1 56 158 6 7 35 2 29 5 28 4 27 5 45	18. 17. 35. 28. 100. Wei 18. 15. 15. 15. 13. 24. 13.	3% 8% 4% 5% 0% <u>std</u> <u>ght ľ</u> 7% 5% 0% 4% 1% 3%	V. Random. 95% C1 - 20 (-0.71, 0.32) - 0.01 (-0.52, 0.52) - 0.01 (-0.57, 0.46) - 0.01 (-0.57, 0.47) - 0.00 (-0.52, 0.52) - 0.00 (-0.52, 0.52) - 0.56 (-1.11, -0.00) - 0.32 (-0.79, 0.33) - 0.32 (-0.79, 0.33)	Favours [Life and concentration]
Jin 2018 Jing 2019 Song 2018 Total (95% Cl) Heterogeneity: Tau ² = 0 Test for overall effect: Z CrS Study or Subgroup Colorge 2023 Hong 2016 Jin 2018 Jun 2022 Song 2018 Yang 2019 Total (95% Cl)	5.63 0.64 5.65 5.15 0.00; Chi ² : = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra 5D 1.29 0.98 0.57 1.3 0.19 1.08	Total 29 28 56 45 158 df = 3 (P) ntion Total 35 29 28 25 45 25 45 25 187	Mean 5.76 0.64 5.74 5.16 = 0.94 Low (<u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13	i 0.65 0.65 0.65 0.61 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32	Total 2 29 7 28 1 56 158 6 7 35 2 29 5 28 4 27 5 45 189 189	18. 17. 28. 100. Weik 18. 15. 15. 13. 24.	3% 8% 4% 5% 0% <u>std</u> <u>ght ľ</u> 7% 5% 0% 4% 1% 3%	V. Random. 95% C1 -0.20 [-0.71, 0.32] -0.00 [-0.52, 0.52] -0.14 [-0.52, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] -0.10 [-0.32, 0.12] -0.10 [-0.57, 0.37] -0.06 [-0.57, 0.46] -0.00 [-0.57, 0.46] -0.00 [-0.52, 0.52] -0.00 [-0.52, 0.52] -0.56 [-1.11, 0.00] -0.12 [-0.30, 0.53]	Favours [Life and concentration]
Jin 2018 Jin 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 East for overall effect: Z CFS Study or Subgroup Calonge 2023 Jong 2016 Jin 2016 Jin 2016 Jin 2018 Song 2018 Yang 2019 Total (95% CI) Heterogeneity: Tau ² = 0	5.63 0.64 5.65 5.15 0.00; Chi ² : = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra 5D 1.29 0.98 0.57 1.3 0.19 1.08 = 4.01, c	Total 29 28 56 45 158 df = 3 (P) ation Total 35 29 28 25 45 25 187 df = 5 (P	Mean 5.76 0.64 5.74 5.16 = 0.94 Low (<u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13	i 0.65 0.65 0.65 0.61 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32	Total 2 29 7 28 1 56 158 6 7 35 2 29 5 28 4 27 5 45 189 189	18. 17. 35. 28. 100. Wei 18. 15. 15. 15. 13. 24. 13.	3% 8% 4% 5% 0% <u>std</u> <u>ght ľ</u> 7% 5% 0% 4% 1% 3%	V. Random. 95% C1 - 20 (-0.71, 0.32) - 0.01 (-0.52, 0.52) - 0.01 (-0.57, 0.46) - 0.01 (-0.57, 0.47) - 0.00 (-0.52, 0.52) - 0.00 (-0.52, 0.52) - 0.56 (-1.11, -0.00) - 0.32 (-0.79, 0.33) - 0.32 (-0.79, 0.33)	Favours [High concentration] Stut Mean Difference IV. Random. 95% C1
Jin 2018 Jin 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 East for overall effect: Z CFS Study or Subgroup Calonge 2023 Jong 2016 Jin 2016 Jin 2016 Jin 2018 Song 2018 Yang 2019 Total (95% CI) Heterogeneity: Tau ² = 0	5.63 0.64 5.65 5.15 0.00; Chi ² : = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra 5D 1.29 0.98 0.57 1.3 0.19 1.08 = 4.01, c	Total 29 28 56 45 158 df = 3 (P) ation Total 35 29 28 25 45 25 187 df = 5 (P	Mean 5.76 0.64 5.74 5.16 = 0.94 Low (<u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13	i 0.65 0.65 0.65 0.61 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32	Total 2 29 7 28 1 56 158 6 7 35 2 29 5 28 4 27 5 45 189 189	18. 17. 35. 28. 100. Wei 18. 15. 15. 15. 13. 24. 13.	3% 8% 4% 5% 0% <u>std</u> <u>ght ľ</u> 7% 5% 0% 4% 1% 3%	V. Random. 95% C1 - 20 (-0.71, 0.32) - 0.01 (-0.52, 0.52) - 0.01 (-0.57, 0.46) - 0.01 (-0.57, 0.47) - 0.00 (-0.52, 0.52) - 0.00 (-0.52, 0.52) - 0.56 (-1.11, -0.00) - 0.32 (-0.79, 0.33) - 0.32 (-0.79, 0.33)	Favours [Ling concentration] Std. Mean Difference IV. Random 395% CI
Jin 2018 Jing 2019 Song 2018 Total (19% CI) Helerogeneity: Tau ² = 0 Helerogeneity: Tau ² = 0 CFS Study or Subgroup Colonge 2023 Hong 2016 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2019 Total (19% CI) Helerogeneity: Tau ² = 0	5.63 0.64 5.65 5.15 0.00; Chi ² : = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra 5D 1.29 0.98 0.57 1.3 0.19 1.08 = 4.01, c	Total 29 28 56 45 158 df = 3 (P) ation Total 35 29 28 25 45 25 187 df = 5 (P	Mean 5.76 0.64 5.74 5.16 = 0.94 Low (<u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13	i 0.65 0.55 0.61 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32	Total 2 29 7 28 1 56 158 6 7 35 2 29 5 28 4 27 5 45 189 189	18. 17. 35. 28. 100. Wei 18. 15. 15. 15. 13. 24. 13.	3% 8% 4% 5% 0% <u>std</u> <u>ght ľ</u> 7% 5% 0% 4% 1% 3%	V. Random. 95% C1 - 20 (-0.71, 0.32) - 0.01 (-0.52, 0.52) - 0.01 (-0.57, 0.46) - 0.01 (-0.57, 0.47) - 0.00 (-0.52, 0.52) - 0.00 (-0.52, 0.52) - 0.56 (-1.11, -0.00) - 0.32 (-0.79, 0.33) - 0.32 (-0.79, 0.33)	Favours [High concentration] Stut Mean Difference IV. Random. 95% C1
Jin 2018 Jin 2019 Song 2018 Total (19% CI) Heterogeneily: Tau ^s = 0 Test for overall effect Z CFS Lange 2023 Joing 2026 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Total (19% CI) Heterogeneily: Tau ^s = 0 Test for overall effect: Z	5.63 0.64 5.65 5.15 0.00; Chi ² = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² = 1.00 (F	0.68 0.56 0.63 0.21 = 0.42, (2 = 0.39) = 0.98 0.57 1.3 0.19 1.08 = 4.01, (2 = 0.32)	Total 29 28 56 45 158 df = 3 (P) tion Total 35 29 28 25 45 28 25 45 187 df = 5 (P)	<u>Mean</u> 5.76 0.64 5.74 5.16 = 0.94 <u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13	: 0.62 0.65 0.66 0.32 0.32 0.12 0.51 0.32 0.32 0.12 0.12 0.52 0.13 0.53 0.32 0.12 0.12 0.53 0.32 0.55 0.32 0.32 0.55 0.32 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.55 0.32 0.55	Total 2 29 7 28 1 56 2 45 158 158 6 7 7 35 2 29 5 28 4 27 5 28 4 25 189 6	18. 17. 35. 28. 100. Weik 18. 15. 13. 24. 13. 100.	3% 8% 4% 5% 0% <u>aht l'</u> 7% 5% 0% 4% 3% 0%	V. Sandom. 95% CI - 0.20 (-0.71, 0.32) 0.00 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.06 (-0.57, 0.57) - 0.06 (-0.57, 0.64) 0.00 (-0.52, 0.52) 0.05 (-1, 11, -0.05) 0.12 (-0.52, 0.52) 0.12 (-0.79, 0.33) -0.10 (-0.31, 0.10) 	Favours (Hgh concentration) Stut Mean Difference N. Random 95% CI
Jin 2018 Jing 2019 Song 2018 Total (19% CI) Heterogeneity: Tau" = 0 Test for overall effect: Z CFS Study or Subgroup Cationge 2023 Hong 2016 Jin 2018 Jun 2022 Song 2018 Yang 2019 Total (19% CI) Heterogeneity: Tau" = 0 Test for overall effect: Z OSDI	5.63 0.64 5.65 5.15 0.00; Chi ² : 2 = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² : 5.82 4.87	0.68 0.56 0.63 0.21 = 0.42, c = 0.39) mcentra 5D 1.29 0.98 0.57 1.3 0.19 1.08 = 4.01, c = 0.32) ligh con	Total 29 28 56 45 158 df = 3 (P) ation Total 35 29 28 25 45 25 187 df = 5 (P) centratic	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 6 Mean 5.49 5.03 0.61 3.2 5.13 = 0.55	: 0.62 0.53 0.63 0.32 0.32 0.53 0.32 0.53 0.11 0.11 0.12 0.15 0.11 0.12 0.15 0.12 0.12 0.12 0.15 0.12	Total 2 29 7 28 1 56 2 45 1 58 7 35 2 29 5 28 4 27 5 28 4 27 5 45 189 6 acentration	18. 17. 35. 28. 100. Wein 18. 15. 13. 24. 13. 100.	33% 88% 4% 55% 0% 9% 7% 7% 55% 0% 4% 4% 33% 0%	V. Random. 95% C1 - 0.20 (-0.71, 0.32) 0.00 (-0.52, 0.52) -0.14 (-0.52, 0.23) -0.04 [-0.42, 0.23] -0.04 [-0.45, 0.38] -0.10 [-0.32, 0.12] Mean Difference V. Random. 95% C1 -0.10 (-0.57, 0.37) -0.06 (-0.57, 0.45) -0.06 (-0.57, 0.57) -0.06 (-0.57, 0.57) -0.06 (-0.57, 0.57) -0.06 (-0.57, 0.57) -0.06 (-0.57, 0.57) -0.06 (-0.57, 0.57) -0.05 (-0.57, 0.	Std. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (19% CI) Heterogeneity: Tau" = 0 Test for overall effect: Z CFS Study or Subgroup Cationge 2023 Hong 2016 Jin 2018 Jun 2022 Song 2018 Yang 2019 Total (19% CI) Heterogeneity: Tau" = 0 Test for overall effect: Z OSDI	5.63 0.64 5.65 5.15 0.00; Chi ² : 2 = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² : 5.82 4.87	0.68 0.56 0.63 0.21 = 0.42, (2 = 0.39) = 0.98 0.57 1.3 0.19 1.08 = 4.01, (2 = 0.32)	Total 29 28 56 45 158 df = 3 (P) ation Total 35 29 28 25 45 25 187 df = 5 (P) centratic	Mean 5.76 0.64 5.74 5.16 = 0.94 Low 6 Mean 5.49 5.03 0.61 3.2 5.13 = 0.55	: 0.62 0.65 0.66 0.32 0.32 0.12 0.51 0.32 0.32 0.12 0.12 0.52 0.13 0.53 0.32 0.12 0.12 0.53 0.32 0.55 0.32 0.32 0.55 0.32 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.32 0.55 0.55 0.32 0.55	Total 2 29 7 28 1 56 2 45 1 58 7 35 2 29 5 28 4 27 5 28 4 27 5 45 189 6 acentration	18. 17. 35. 28. 100. Wein 18. 15. 13. 24. 13. 100.	3% 8% 4% 5% 0% <u>aht l'</u> 7% 5% 0% 4% 3% 0%	V. Sandom. 95% CI - 0.20 (-0.71, 0.32) 0.00 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.04 (-0.52, 0.52) - 0.06 (-0.57, 0.57) - 0.06 (-0.57, 0.64) 0.00 (-0.52, 0.52) 0.05 (-1, 11, -0.05) 0.12 (-0.52, 0.52) 0.12 (-0.79, 0.33) -0.10 (-0.31, 0.10) 	Favours (Hgh concentration) Stut Mean Difference N. Random 95% CI
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z CrS Study or Subgroup Calonge 2023 Horng 2019 Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z OSDI Study or Subgroup	5.63 0.64 5.65 5.15 0.00; Chi ² = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.0; Chi ² = 1.00 (F	0.68 0.56 0.63 0.21 = 0.42, (9 = 0.39) mcentra 5D 1.29 0.98 1.3 0.19 1.08 = 4.01, (9 = 0.32) ligh con lean	Total 29 28 66 45 158 158 45 158 158 off = 3 (P) 100 totion 35 29 28 25 187 df = 5 (P) 0 ccentratic SD	Mean 5.76 0.64 5.74 5.74 5.16 = 0.94 Mean 5.49 5.03 0.61 3.2 5.8 5.13 = 0.55	i 0.62 i 0.63 i 0.63 i 0.63 i 0.32 concent <u>ST</u> 0.1,17 1.17 0.9 2.4 0.1,17 1.17 1.17 0.9 1.17 1.17 0.9 2.4 0.17 1.17 1.17 0.9 2.4 0.17 1.17	D Total 2 29 2 28 1 56 2 45 158 158 0 Total 7 35 2 29 5 28 4 27 5 45 189 6 SD	18.3 17.3 35.2 28.3 100. 18. 15.3 15.3 13.2 24. 13.3 100. n n iotal 1	33% 8% 5% 00% <u>9ht ľ</u> 7% 5% 0% 4% 1% 3% 0% Weight	V. Random. 95% CI -0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] -0.41 [-0.52, 0.52] -0.41 [-0.52, 0.52] -0.41 [-0.52, 0.52] -0.41 [-0.52, 0.53] -0.41 [-0.57, 0.57] -0.41 [-0.57, 0.57] -0.41 [-0.57, 0.57] -0.56 [-1.17, 0.65] -0.52 [-0.79, 0.33] -0.12 [-0.30, 0.53] -0.12 [-0.30, 0.55] -0.22 [-0.79, 0.33] -0.10 [-0.31, 0.10] Std. Mean Difference V. Random. 95% CI	Std. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (19% CI) Heterogeneity: Tau* = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018 Jin 2018 Jing 2018 Jing 2018 Yang 2019 Total (19% CI) Heterogeneity: Tau* = 0 Uma tor overall effect: Z OSDI Study or Subgroup Calonge 2023	5.63 0.64 5.65 5.15 0.00; Chi ² = 0.87 (F High co <u>Mean</u> 5.37 0.61 2.1 5.82 4.87 0.00; Chi ² = 2.82 4.87 0.00; Chi ² = 4.87 0.00; Chi ² = 3.82 4.87 0.00; Chi ² = 3.82 4.87	0.68 0.56 0.63 0.21 = 0.42, (, 0.39) encentra 5D 0.98 0.57 1.29 0.98 0.57 1.3 0.19 1.08 = 4.01, (= 0.32) iigh con lean 7.54 1	Total 29 28 56 45 158 158 3(P 355 29 28 25 187 45 158 29 28 25 187 5(P 187 5(P 187 16(P 25 187 187 5(P 187 14.79	<u>Mean</u> 5.76 0.64 5.74 5.16 = 0.94 <u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13 = 0.55 0 n <u>Total</u> 35	i 0.63 i 0.63 i 0.51 i 0.63 i 0.32 concent SIT 0.1 i 1.12 0.9 i 2.43 0.1 i 1.12 0.9 i 2.43 0.1 i 1.12 0.9 i 2.43 0.1 i 0.51 i 0.52 i 0.55 i 0.5	Total 2 29 7 28 56 158 1 56 7 35 2 45 1 58 7 35 2 29 5 28 4 27 5 45 189 6 17.87	18.3 17.3 35.2 28.3 100. 18. 15.3 15.3 13.2 24. 13.3 100. n <u>otal 1</u> 35	33% 88% 55% 00% <u>Std</u> <u>9ht ľ</u> 77% 55% 00% 4% 1% 33% 00% <u>Weight</u> 35.4%	V. Random. 95% C1 - 0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] - 0.04 [-0.52, 0.23] - 0.04 [-0.52, 0.23] - 0.04 [-0.52, 0.23] - 0.04 [-0.52, 0.23] - 0.10 [-0.57, 0.37] - 0.10 [-0.57, 0.37] - 0.06 [-0.57, 0.45] - 0.05 [-0.14] - 0.15 [-0.52, 0.52] - 0.5 [-0.52] - 0.5	Std. Mean Difference N. Random 55% Cl Favours [High concentration] Std. Mean Difference N. Random 55% Cl Std. Std. Std. Cl Std. Mean Difference Std. Mean Difference Std. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Jin 2018 Jin 2018 Song 2018 Song 2018 Song 2018 Total (95% CI) Heterogeneity: Tau ² = 0 Test for overall effect: Z OSDI Study or Subgroup Calonge 2023 Jun 2022	5.63 0.64 5.65 5.15 2 = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² : 2 = 1.00 (F H M M	0.68 0.56 0.63 0.21 = 0.42, (9 = 0.39) = 0.39) = 0.39 1.29 0.98 0.57 1.3 0.19 1.08 = 0.32) ligh con lean 7.54 1 51.9	Total 29 28 56 45 158 158 64 159 30 ation Total 35 29 28 25 45 25 187 ff = 5 (P ocentratic SD 4ff = 5 (P 17.3	<u>Mean</u> 5.76 0.64 5.74 5.16 = 0.94, <u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13 = 0.55 0 m <u>fotal</u> 35 25	$\begin{array}{cccc} & 0.63 \\ & 0.51 \\ & 0.63 \\ & 0.63 \\ & 0.63 \\ \end{array}$	D Total 2 29 7 28 7 28 56 2 56 2 45 158 5 5 2 29 7 35 2 29 7 35 2 29 7 35 2 29 5 2 29 5 2 29 5 2 29 5 2 29 5 2 4 27 5 4 25 189 6 6 50 1 17.87 16.9 16.9 16.9 10.0 10.	18. 17. 35. 28. 100. Weit 18. 15. 15. 13. 24. 13. 24. 13. 100. n <u>otal 1</u> 35. 27	3% 8% 8% 0% 5% 0% 5% 5% 5% 0% 4% 1% 3% 0% 0% 0% 0%	V. Random. 95% CI - 0.20 (−7,1,0.32) 0.00 (−0.52,0.52) − 0.41 (−0.52,0.52) − 0.41 (−0.52,0.52) − 0.41 (−0.52,0.52) − 0.41 (−0.52,0.53) − 0.41 (−0.52,0.53) − 0.41 (−0.52,0.53) − 0.41 (−0.53,0.53) − 0.42 (−0.53,0.53) − 0.42 (−0.79,0.33) − 0.42 (−0.43,0.54) − 0.42 (−0.43,0.54) − 0.42 (−0.43,0.54) − 0.43 (−0.43	Std. Mean Difference
un 2018 Ung 2019 Song 2018 Total (9% C) Heterogeneity: Tau" = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Ung 2018 Vang 2019 Total (9% C) Heterogeneity: Tau" = 0 Total (9% C) Heterogeneity: Tau" = 0 Total (9% C) Heterogeneity: Tau" = 0 Study or Subgroup Calonge 2023 Ung 2022	5.63 0.64 5.65 5.15 2 = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² : 2 = 1.00 (F H M M	0.68 0.56 0.63 0.21 = 0.42, (9 = 0.39) = 0.39) = 0.39 1.29 0.98 0.57 1.3 0.19 1.08 = 0.32) ligh con lean 7.54 1 51.9	Total 29 28 56 45 158 158 3(P 355 29 28 25 187 45 158 29 28 25 187 5(P 187 5(P 187 16(P 25 187 187 5(P 187 14.79	<u>Mean</u> 5.76 0.64 5.74 5.16 = 0.94 <u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13 = 0.55 0 n <u>Total</u> 35	i 0.63 i 0.63 i 0.51 i 0.63 i 0.32 concent SIT 0.1 i 1.12 0.9 i 2.43 0.1 i 1.12 0.9 i 2.43 0.1 i 1.12 0.9 i 2.43 0.1 i 0.51 i 0.52 i 0.55 i 0.5	Total 2 29 7 28 56 158 1 56 7 35 2 45 1 58 7 35 2 29 5 28 4 27 5 45 189 6 17.87	18.3 17.3 35.2 28.3 100. 18. 15.3 15.3 13.2 24. 13.3 100. n <u>otal 1</u> 35	33% 88% 55% 00% <u>Std</u> <u>9ht ľ</u> 77% 55% 00% 4% 1% 33% 00% <u>Weight</u> 35.4%	V. Random. 95% C1 - 0.20 [-0.71, 0.32] 0.00 [-0.52, 0.52] - 0.04 [-0.52, 0.23] - 0.04 [-0.52, 0.23] - 0.04 [-0.52, 0.23] - 0.04 [-0.52, 0.23] - 0.10 [-0.57, 0.37] - 0.10 [-0.57, 0.37] - 0.06 [-0.57, 0.45] - 0.05 [-0.14] - 0.15 [-0.52, 0.52] - 0.5 [-0.52] - 0.5	Std. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (19% CI) Heterogeneity: Tau* = 0 Test for overall effect: Z CrS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018 Jing 20	5.63 0.64 5.65 5.15 0.00; Chi ² := 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² := 1.00 (F H M 0.00; Chi ² := 1.00 (F	$\begin{array}{l} 0.68\\ 0.56\\ 0.63\\ 0.21\\ \end{array}$	Total 29 29 28 56 45 158 3f = 3 (P off = 3 (P 29 28 25 187 45 25 187 16f = 5 (P) centratic SD SD 17.3 4.89	<u>Mean</u> 5.76 0.64 5.76 5.76 = 0.94 <u>Mean</u> 5.49 5.03 0.61 3.2 2.5 8.8 5.13 = 0.55 0 0 10 10 12 5.7 15	i 0.62 i 0.55 i 0.61 i 0.61 i 0.61 i 0.61 i 0.32 concent SEC 1.17 i 1.17 i 1.17 i 1.17 i 1.17 i 1.17 i 0.44 i 0.18 i 0.18 i 0.61 i 0.32 concent I 1.17 i 1	D Total 2 29 7 28 1 56 1 56 1 56 1 56 1 56 1 56 1 5 2 29 5 25 4 27 5 45 5 20 6 189 6 10.9 6 116.9 2.69 2.69	18.3 17.3 35.28.3 100. 18.3 15.3 13.3 24. 13.3 24. 13.3 100. 13.3 24. 13.3 100. 13.3 13.3 24. 13.3 100. 13.3 100. 13.5 13.5 13.5 13.5 13.5 13.5 13.5 13.	3% 8% 8% 9% 0% 1% 7% 5% 4% 4% 4% 4% 3% 3% 0% 0% 0% 0% 0% 0% 18.28.6% 18.2%	V. Random. 95% C1 - 0.20 (− 7), 0.32) 0.00 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.10 (− 0.57, 0.37) - 0.06 (− 0.57, 0.457) - 0.05 (− 0.45, 0.454) - 0.05 (− 0.45, 0.454) - 0.05 (− 0.45, 0.54) - 0.05 (−	Std. Mean Difference N. Random 55% Cl Favours [High concentration] Std. Mean Difference N. Random 55% Cl Std. Std. Std. Cl Std. Mean Difference Std. Mean Difference Std. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (9% CI) Heterogeneity: Tau* = 0 Test for overall effect: Z CrS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018 Jing 2018 Jing 2018 Jing 2018 Jing 2018 Jing 2018 Jing 2018 Jing 2018 Jing 2018 Total (9% CI) Heterogeneity: Tau* = 0 Costor Study or Subgroup Calonge 2023 Jing 2022 Zing 2018 (Mid type)	5.63 0.64 5.65 5.15 0.00; Chi ² := 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² := 1.00 (F H M 0.00; Chi ² := 1.00 (F	$\begin{array}{l} 0.68\\ 0.56\\ 0.63\\ 0.21\\ \end{array}$	Total 29 28 56 45 158 158 64 159 30 ation Total 35 29 28 25 45 25 187 ff = 5 (P ocentratic SD 4ff = 5 (P 17.3	<u>Mean</u> 5.76 0.64 5.74 5.16 = 0.94, <u>Mean</u> 5.49 5.03 0.61 3.2 5.8 5.13 = 0.55 0 m <u>fotal</u> 35 25	$\begin{array}{cccc} & 0.63 \\ & 0.51 \\ & 0.63 \\ & 0.63 \\ & 0.63 \\ \end{array}$	D Total 2 29 7 28 7 28 56 52 52 45 158 56 52 29 52 29 52 29 52 29 53 28 27 55 4 25 189 56 6 17.787 16.9 17.87 16.9	18. 17. 35. 28. 100. Weit 18. 15. 15. 13. 24. 13. 24. 13. 100. n <u>otal 1</u> 35. 27	3% 8% 8% 0% 5% 0% 5% 5% 5% 0% 4% 1% 3% 0% 0% 0% 0%	V. Random. 95% CI - 0.20 (−7,1,0.32) 0.00 (−0.52,0.52) − 0.41 (−0.52,0.52) − 0.41 (−0.52,0.52) − 0.41 (−0.52,0.52) − 0.41 (−0.52,0.53) − 0.41 (−0.52,0.53) − 0.41 (−0.52,0.53) − 0.41 (−0.53,0.53) − 0.42 (−0.53,0.53) − 0.42 (−0.79,0.33) − 0.42 (−0.43,0.54) − 0.42 (−0.43,0.54) − 0.42 (−0.43,0.54) − 0.43 (−0.43	Std. Mean Difference
Jin 2018 Jing 2019 Song 2018 Total (19% CI) Heterogeneity: Tau" = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2018 Jin 2018 Jing 2018 Jing 2018 Jing 2018 Jing 2018 Total (19% CI) Heterogeneity: Tau" = 0 Test for overall effect: Z OSDI Calonge 2023 Jun 2022 Zheng 2018 (Severe typ	5.63 0.64 5.65 5.15 0.00; Chi ² := 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² := 1.00 (F H M 0.00; Chi ² := 1.00 (F	$\begin{array}{l} 0.68\\ 0.56\\ 0.63\\ 0.21\\ \end{array}$	Total 29 29 28 56 45 158 3f = 3 (P off = 3 (P 29 28 25 187 45 25 187 16f = 5 (P) centratic SD SD 17.3 4.89	<u>Mean</u> 5.76 0.64 5.74 5.74 5.16 = 0.94 5.03 0.61 3.2 5.8 5.13 = 0.55 0 n <u>fotal</u> 35 25 15 15	i 0.62 i 0.55 i 0.61 i 0.61 i 0.61 i 0.32 concent SEC 1.17 i 1.17 i	D Total 2 29 7 28 1 56 1 56 1 56 1 56 1 56 1 56 1 5 2 29 5 25 4 27 5 45 5 20 6 189 6 10.9 6 116.9 2.69 2.69	18.3 17.3 35.2 28.3 1000. 18.1 5.3 15.3 15.3 15.3 1000. 13.3 24. 13.3 1000. 13.5 27 15 15	3% 8% 8% 0% Std 9% 7% 5% 5% 5% 5% 5% 0% 4% 33% 0% Weight 33% 0% UNE 86% 18.2% 18.2% 17.8%	V. Random. 95% C1 - 0.20 (− 7), 0.32) 0.00 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.06 (− 0.57, 0.37) - 0.06 (− 0.57, 0.47) - 0.05 (− 1.17, 0.07) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.06 (− 0.57, 0.47) - 0.05 (− 0.17, 0.17) - 0.05 (− 0.17, 0.13) - 0.57 (− 0.17, 1.30) - 0.57	Std. Mean Difference
Jin 2018 Jing 2019 Song 2020 Total (95% CI) Heterogeneity: Trau* = 0 Test for overall effect: Z CrS Study or Subgroup Calonge 2023 Hong 2018 Jin 2018 Jing 2018 Jing 2018 Jing 2018 Total (95% CI) Heterogeneity: Trau* = 0 Test for overall effect: Z OSDI Study or Subgroup Calonge 2023 Jing 2028 Zeng 2018 (Severe typ	5.63 0.64 5.65 5.15 0.00; Chi ² := 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 4.87 0.00; Chi ² := 1.00 (F H M 0.00; Chi ² := 1.00 (F	$\begin{array}{l} 0.68\\ 0.56\\ 0.63\\ 0.21\\ \end{array}$	Total 29 29 28 56 45 158 3f = 3 (P off = 3 (P 29 28 25 187 45 25 187 16f = 5 (P) centratic SD SD 17.3 4.89	<u>Mean</u> 5.76 0.64 5.76 5.76 = 0.94 <u>Mean</u> 5.49 5.03 0.61 3.2 2.5 8.8 5.13 = 0.55 0 0 10 10 12 5.7 15	i 0.62 i 0.55 i 0.61 i 0.61 i 0.61 i 0.32 concent SEC 1.17 i 1.17 i	D Total 2 29 7 28 1 56 1 56 1 56 1 56 1 56 1 56 1 5 2 29 5 25 4 27 5 45 5 20 6 189 6 10.9 6 116.9 2.69 2.69	18.3 17.3 35.2 28.3 1000. 18.1 5.3 15.3 15.3 15.3 1000. 13.3 24. 13.3 1000. 13.5 27 15 15	3% 8% 8% 9% 0% 1% 7% 5% 4% 4% 4% 4% 3% 3% 0% 0% 0% 0% 0% 0% 18.28.6% 18.2%	V. Random. 95% C1 - 0.20 (− 7), 0.32) 0.00 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.10 (− 0.57, 0.37) - 0.06 (− 0.57, 0.457) - 0.05 (− 0.45, 0.454) - 0.05 (− 0.45, 0.454) - 0.05 (− 0.45, 0.54) - 0.05 (−	Std. Mean Difference
un 2018 Jung 2019 Song 2020 Total (95% C) Heterogeneity: Tau" = 0 Test for overall effect: Z CSUS or Subgroup Hong 2012 Jun 2022 Song 2018 Jun 2022 Song 2018 Total (95% C) Heterogeneity: Tau" = 0 Study or Subgroup Calonge 2023 Jung 2022 Zheng 2016 (Mild type) Total (95% CC)	5.63 0.64 5.65 5.15 0.00; Chi ² + High coo Mean 5.37 0.61 2.1 5.82 4.87 0.61 2.1 5.82 4.87 0.00; Chi ² + 0.61 2.100 (F	$\begin{array}{l} 0.68\\ 0.56\\ 0.63\\ 0.21\\ \end{array}$	Total 29 28 56 56 45 158 67 attion 70 35 29 28 25 48 25 187 57 275 28 28 25 48 25 187 71 35 29 4.83 4.83	<u>Mean</u> 5.76 0.64 5.74 5.74 5.16 = 0.94 <u>Mean</u> 5.49 5.061 3.2 5.8 5.13 = 0.55 0.61 3.2 5.8 5.13 35 25 15 15 15 90	$\begin{array}{rcl} & 0.62\\ & 0.55\\ & 0.6\\ & 0.6\\ & 0.3$	D Total 2 29 7 28 1 56 1 56 1 56 1 56 1 56 1 56 1 5 2 29 5 25 4 27 5 45 5 20 6 189 6 10.9 6 116.9 2.69 2.69	18.3 17.3 35.2 28.3 1000. 18.1 5.3 15.3 15.3 15.3 1000. 13.3 24. 13.3 1000. 13.5 27 15 15	3% 8% 8% 0% Std 9% 7% 5% 5% 5% 5% 5% 0% 4% 33% 0% Weight 33% 0% UNE 86% 18.2% 18.2% 17.8%	V. Random. 95% C1 - 0.20 (− 7), 0.32) 0.00 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.06 (− 0.57, 0.37) - 0.06 (− 0.57, 0.47) - 0.05 (− 1.17, 0.07) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.06 (− 0.57, 0.47) - 0.05 (− 0.17, 0.17) - 0.05 (− 0.17, 0.13) - 0.57 (− 0.17, 1.30) - 0.57	Favours (High concentration) Std. Mean Difference IV. Random, 85%, Cl Favours (High concentration) Std. Mean Difference IV. Random, 85%, Cl Favours (High concentration) Std. Mean Difference IV. Random, 85%, Cl
Jin 2018 Jing 2019 Song 2018 Total (19% C1) Heterogeneity: Tau" = 0 Test for overall effect: Z CFS Study or Subgroup Calonge 2023 Hong 2016 Jin 2018 Jin 2018 Jing 2018 Yang 2019 Total (19% C1) Heterogeneity: Tau" = 0. Calonge 2023 Jun 2022 Zheng 2018 (Mild type) Zheng 2018 (Severe typ Total (19% C1) Heterogeneity: Tau" = 0.	5.63 0.64 5.65 5.15 0.00; ChiP 14 = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 2.1 5.82 4.87 0.0; ChiP 14 = 1.00 (F H Man 3 3 3 3 5.85 5.15	$\begin{array}{l} 0.68\\ 0.56\\ 0.63\\ 0.21\\ \end{array}$	Total 29 28 56 56 45 158 67 attion 70 35 29 28 25 48 25 187 57 275 28 28 25 48 25 187 71 35 29 4.83 4.83	<u>Mean</u> 5.76 0.64 5.74 5.74 5.16 = 0.94 <u>Mean</u> 5.49 5.061 3.2 5.8 5.13 = 0.55 0.61 3.2 5.8 5.13 35 25 15 15 15 90	$\begin{array}{rcl} & 0.62\\ & 0.55\\ & 0.6\\ & 0.6\\ & 0.3$	D Total 2 29 7 28 1 56 1 56 1 56 1 56 1 56 1 56 1 5 2 29 5 25 4 27 5 45 5 20 6 189 6 10.9 6 116.9 2.69 2.69	18.3 17.3 35.2 28.3 1000. 18.1 5.3 15.3 15.3 15.3 1000. 13.3 24. 13.3 1000. 13.5 27 15 15	3% 8% 8% 0% Std 9% 7% 5% 5% 5% 5% 5% 0% 4% 33% 0% Weight 33% 0% UNE 86% 18.2% 18.2% 17.8%	V. Random. 95% C1 - 0.20 (− 7), 0.32) 0.00 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.06 (− 0.57, 0.37) - 0.06 (− 0.57, 0.47) - 0.05 (− 1.17, 0.07) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.06 (− 0.57, 0.47) - 0.05 (− 0.17, 0.17) - 0.05 (− 0.17, 0.13) - 0.57 (− 0.17, 1.30) - 0.57	Favours [High concentration] Std. Mean Difference V. Random. 85%. Cl G Favours [High concentration] Std. Occupation Std. Mean Difference V. Random. 85%. Cl G Favours [High concentration] Std. Mean Difference Std. Mean Difference
Jin 2018 Jin 2019 Song 2019 Total (9% CI) Heterogeneity: Tau* = 0 Test for overall effect: Z CFS or Subproup Hong 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2018 Jin 2019 Total (9% CI) Test (for overall effect: Z 2051 Study or Subgroup Latonge 2023 Jin 2022 Pring 2018 (Mild type) Zheng 2018 (Mild type) Total (9% CI)	5.63 0.64 5.65 5.15 0.00; ChiP 14 = 0.87 (F High co Mean 5.37 4.97 0.61 2.1 5.82 2.1 5.82 4.87 0.0; ChiP 14 = 1.00 (F H Man 3 3 3 3 5.85 5.15	$\begin{array}{l} 0.68\\ 0.56\\ 0.63\\ 0.21\\ \end{array}$	Total 29 28 56 56 45 158 67 attion 70 35 29 28 25 48 25 187 57 275 28 28 25 48 25 187 71 35 29 4.83 4.83	<u>Mean</u> 5.76 0.64 5.74 5.74 5.16 = 0.94 <u>Mean</u> 5.49 5.061 3.2 5.8 5.13 = 0.55 0.61 3.2 5.8 5.13 35 25 15 15 15 90	$\begin{array}{rcl} & 0.62\\ & 0.55\\ & 0.6\\ & 0.6\\ & 0.3$	D Total 2 29 7 28 1 56 1 56 1 56 1 56 1 56 1 56 1 5 2 29 5 25 4 27 5 45 5 20 6 189 6 10.9 6 116.9 2.69 2.69	18.3 17.3 35.2 28.3 1000. 18.1 5.3 15.3 15.3 15.3 1000. 13.3 24. 13.3 1000. 13.5 27 15 15	3% 8% 8% 0% Std 9% 7% 5% 5% 5% 5% 5% 0% 4% 33% 0% Weight 33% 0% UNE 86% 18.2% 18.2% 17.8%	V. Random. 95% C1 - 0.20 (− 7), 0.32) 0.00 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.04 (− 0.52, 0.52) - 0.06 (− 0.57, 0.37) - 0.06 (− 0.57, 0.47) - 0.05 (− 1.17, 0.07) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.15 (− 0.62, 0.52) - 0.06 (− 0.57, 0.47) - 0.06 (− 0.57, 0.47) - 0.05 (− 0.17, 0.17) - 0.05 (− 0.17, 0.13) - 0.57 (− 0.17, 1.30) - 0.57	Favours (High concentration) Std. Mean Difference IV. Random, 95%.Cl Favours (High concentration) Std. Mean Difference IV. Random, 95%.Cl Favours (High concentration) Std. Mean Difference IV. Random, 95%.Cl

Figure 3 Forest plot results for each baseline data.




Figure 4 Forest plot and Egger's test of Schirmer's I test.

test demonstrated no publication bias (P=0.857). According to region, Meta-regression analysis did not identify the source of heterogeneity (Figure 8).

Sensitivity Analysis and Meta-regression We performed sensitivity analyses to analyze the heterogeneity factors. The results were all between the upper and lower limits of the CI, and the conclusions were relatively stable. Only the SIT result showed a significant rightward shift in the CI (Figure 9).

Further, we performed Meta-regression and did not find the source of heterogeneity (Figure 10).

DISCUSSION

It is widely recognized that DES arises from reduced tear secretion or increased tear evaporation, leading to conditions such as aqueous-deficient dry eye and evaporative dry eye^[32-33]. HY is increasingly being used in patients with all types of dry eye due to its excellent hydrating and lubricating capabilities. A prior Meta-analysis demonstrated a noteworthy enhancement in the SIT test score subsequent to using HY eye drops when compared to non-HY treatment^[20]. However, no statistically significant results were observed, including for TBUT and OSDI^[34], and there were no comparison of the impact of changes in concentration on dry eye symptoms. This study mainly compared the effect of high concentration of HY (0.3%) and low concentration of HY (0.1%, 0.15%, 0.18%) in treating dry eye patients, including SIT, TBUT, CFS, DESS, and OSDI results, whereas none of the previous Meta-analyses compared the effect of high and low concentrations of HY eye drops on dry eye.

Generally, low-concentration of HY is suggested for mild DES, and high-concentration of HY is advised for severe DES. This article provides some evidence of the superiority




Figure 5 Forest plot and Egger's test, Trim and Fill analysis of tear breakup time.




Figure 6 Forest plot and Egger's test of dry eye symptom score.

of high-concentration HY in the treatment of DES. The CFS significantly decreased in the high-concentration group compared to the low-concentration group (SMD -3.37; 95%CI -5.25, -1.48) with high heterogeneity (I^2 =98%, P<0.00001). Similarly, relevant animal studies demonstrating significantly lower CFS in the higher concentration HY group compared to the lower concentration groups^[35]. However, none of the other results we analyzed were statistically significant, but through forest plots of DESS and OSDI we found that high concentration group is favoured. We initially thought that a higher concentration of HY would be more beneficial. Although some academics have argued that characterizing low concentration of HY as sufficient for mild cases of dry eyes, while higher concentration are better suited to severe instances, this argument is inaccurate^[36-37].

The SIT, which quantifies tear production, is a prevalent diagnostic technique in DES^[38]. The SIT did not yield any statistically significant difference between the high and low concentration groups (WMD 0.57; 95%CI: 0.15, 1.29) as

well as high heterogeneity ($I^2=80\%$, P=0.002). We identified the study conducted by Jin and Dang^[23], which seemed to be responsible for the observed heterogeneity. By excluding this study, the heterogeneity was reduced to 0 ($I^2=0$) and significant changes were observed (P<0.00001). However, the Metaregression analysis did not reveal the source of heterogeneity. For one thing, this may have to do with the limitations of testing. The absence of standardised placement of paper strips, along with uneven absorption upon tearing, the imprecise correlation between liquid absorption and humidification length of the strip, and the deficiency of standardised assessment methods all contribute to low reproducibility, sensitivity, and specificity of SIT. This may lead to inaccurate results^[39]. On the other hand, clinicians often rely on the SIT to determine whether the eye is aqueous-deficient dry eye. Since none of the studies we included differentiated between aqueous-deficient dry eye and evaporative dry eye and HY does not belong to the class of medications that promote tear secretion, it is not unlikely that the SIT is not statistically significant. Although some researchers have argued that the SIT is not sensitive enough to be useful as a tool for patients with non-severe DES^[40]. Nevertheless, the SIT continues to be used as a standard diagnostic tool for DES monitoring.

Like the SIT, TBUT results were also statistically insignificant (P=0.35) and demonstrated high heterogeneity (I^2 =98%), but sensitivity analysis showed that the results were stable. TBUT mainly evaluates the tear film in cases of evaporative DES^[41]. A previous Meta-analysis demonstrated a lesser improvement in TBUT following the use of a hyaluronan-based treatment^[42]. From the results of the current study, the increase in HY concentration also did not improve TBUT. It may be due to the instability of the tear film itself. False tear film rupture




Figure 7 Forest plot and Egger's test, Trim and Fill analysis of corneal fluorescein staining score.




Figure 8 Forest plot and Egger's test of ocular surface disease index.

may occur as a result of lipid layer diffusion and absorption into the mucus-water interface or due to the rupture of the least strong region of the mucus layer^[43]. Simultaneously, the test has no standardized procedure for the application of fluorescein, which can lead to inaccurate results. Although it has been labeled inaccurate and non-reproducible^[44], it is still recommended to be routinely assessed in clinical practice by measuring TBUT^[45].

Both DESS and OSDI reflect the eye's subjective perception, and the scores are largely limited by the patient's tolerance and corneal sensitivity. It is established that such subjective test yields more dependable and replicable outcomes than alternative objective measures^[46]. Although neither metric was statistically significant, the forest plot favoured the higher concentration group, so we think it still proves the advantage of the higher concentration group. However, corneal nerve damage resulting from prolonged DES is a well-established phenomenon. This can lead to reduced corneal sensitivity, which may obscure symptoms of discomfort within the

1116

eye^[47]. At the same time, the selection of rating scales was not standardized, and the degree of dry eye in the study population was different. All of these factors affect the accuracy of the final scoring results. Further, Egger's regression test revealed no evidence of publication bias, and Meta-regression analyses failed to identify the origin of heterogeneity, thus indicating relatively dependable outcomes.

Combining the above results, this is probably related to the physicochemical properties of HY. Inflammation has been identified as the pathogenic mechanism of dry eye disease^[48]. High molecular weight hyaluronic acid is an anti-inflammatory mediator, while low molecular weight hyaluronic acid is a pro-inflammatory mediator^[49-51]. Therefore, HY plays an important role in patients with moderate or severe dry eye and superficial keratitis, especially in patients with dry eye accompanied by inflammation^[52]. The impact of HY on DES treatment is attributable to diverse mechanisms of action, including stabilizing the ocular surface barrier and tear film, reducing mechanical damage of the cornea^[53], increasing cell adhesion and motility^[54] and promoting cellular migration^[55], and reducing tear evaporation^[56]. Hence the choice of treating dry eye with HY preparations.

However, raising the concentration of HY alone may not provide the anticipated benefits. Due to variations in molecular weight and polydispersity index among the HY formulations utilized, as well as other physico-chemical characteristics, which can have a notable influence on the overall viscosity and clinical applications of HY^[57]. HY solutions are commonly prescribed as the major treatment for moderate to severe DES in clinical practice, due to their anti-inflammatory and immunomodulatory properties^[58], but the effect varies from person to person. As a result, drug companies attempt to improve the efficacy of HY by increasing the concentration




Figure 9 Sensitivity analysis of each result SIT: Schirmer's I test; TBUT: Tear break-up time; DESS: Dry eye symptom score; CFS: Corneal fluorescein staining score; OSDI: Ocular Surface Disease Index.

SIT_ES	Coefficient	: Std. err.	t	P> t	[95% conf.	interval]
region _cons	1361697 .8093629	.9132879 1.646383	-0.15 0.49	0.895 0.672	-4.06573 -6.27445	3.793391 7.893176
TBUT	ES Coeffic	ient Std. err.	t	P> t	[95% conf.	interval]
Otherinterventi			0.85 0.29	0.428 0.784	-2.498328 -2.537925	5.157583 3.211952
DESS_ES	Coefficien	t Std. err.	t	P> t	[95% conf.	interval]
period _cons	-2.803843 2.661658	2.717438 4.291125	-1.03 0.62	0.411 0.598	-14.49604 -15.80156	8.888351 21.12488
CFS _	ES Coeffic	ient Std. err.	t t	P> t	[95% conf	. interval]
Otherinterventi _co	and the second sec		-0.74 -0.06		-43.56151 -27.8481	27.03867 26.74146
OSDI _ES	Coefficier	t Std. err.	t	P> t	[95% conf.	interval]
region _cons	0160693 218113		-0.02 -0.19	0.985 0.867	-3.215827 -5.160241	3.183688 4.724015

Figure 10 Meta-regression of each result.

and improving the ratio, and of course this behaviour is beneficial.

The study's primary limitation concerns the heterogeneity of the included studies. Differences in research design between studies (random assignment method and blind method), characteristics of subjects (differences in age, followup period, region, requires surgery, other intervention) in particular severity of DES, and whether hyaluronic acid contains preservatives are not clearly stated in the vast majority of literature. The original study also did not specify when the test was performed (how long after the eye drops were administered). These factors could have influenced the outcomes of this research. Based on it. First, Table 1 provides a detailed overview of the critical characteristics of each study to enhance the contextualization of our findings. Second, we tried to find points of difference (region, other interventions) in the literature for each outcome, looking for sources of heterogeneity through Meta-regression. Finally, we chose a follow-up period of 4-5wk for all included studies to minimize the effect of this factor. Because the one with a 5-week followup was a high-quality study, we did not exclude it.

This review analyzed ten clinical trials that compared the effectiveness of various concentrations of HY. The Metaanalysis demonstrated that high concentrations of HY were more effective in improving CFS than low concentrations. However, they were found to be ineffective in improving other indicators, particularly SIT and TBUT. Although the high concentration group showed some benefits in DESS and OSDI, which may enhance the subjective experience of patients, it was not statistically significant. Therefore, it is advisable to use higher concentrations of HY for the treatment of dry eye with corneal staining. The main limitation of this study is the inter-study heterogeneity, which suggests that a prominent human RCT with a standardized protocol is needed to properly assess the relative efficacy of high-concentration versus low-concentration artificial tear preparations.

ACKNOWLEDGEMENTS

Conflicts of Interest: Ouyang XW, None; Fang S, None; Yi YM, None; Zou SP, None; Hu QY, None; Huang ZX, None; Li QX, None; Luo JY, None. REFERENCES

1 Sheppard J, Shen Lee B, Periman LM. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists. *Ann Med* 2023;55(1):241-252.

- 2 Okumura Y, Inomata T, Iwata N, Sung J, Fujimoto K, Fujio K, Midorikawa-Inomata A, Miura M, Akasaki Y, Murakami A. A review of dry eye questionnaires: measuring patient-reported outcomes and health-related quality of life. *Diagnostics* 2020;10(8):559.
- 3 Boboridis KG, Messmer EM, Benítez-Del-Castillo J, Meunier J, Sloesen B, O'Brien P, Quadrado MJ, Rolando M, Labetoulle M. Patient-reported burden and overall impact of dry eye disease across eight European countries: a cross-sectional web-based survey. *BMJ Open* 2023;13(3):e067007.
- 4 Zhou QJ, Yang LL, Wang Q, Li Y, Wei C, Xie LX. Mechanistic investigations of diabetic ocular surface diseases. *Front Endocrinol* 2022;13:1079541.
- 5 Carreno-Galeano JT, Dohlman TH, Kim S, Yin J, Dana R. A review of ocular graft-versus-host disease: pathophysiology, clinical presentation and management. *Ocul Immunol Inflamm* 2021;29(6):1190-1199.
- 6 Shah R, Amador C, Tormanen K, Ghiam S, Saghizadeh M, Arumugaswami V, Kumar A, Kramerov AA, Ljubimov AV. Systemic diseases and the cornea. *Exp Eye Res* 2021;204:108455.
- 7 Hat K, Kaštelan S, Planinić A, Muller D, Ježek D. Pathohistological features of the aging human lacrimal gland. *Croat Med J* 2023;64(5): 307-319.
- 8 Sheppard JD, Nichols KK. Dry eye disease associated with meibomian gland dysfunction: focus on tear film characteristics and the therapeutic landscape. *Ophthalmol Ther* 2023;12(3):1397-1418.
- 9 Salinas R, Puig M, Fry CL, Johnson DA, Kheirkhah A. Floppy eyelid syndrome: a comprehensive review. *Ocul Surf* 2020;18(1):31-39.
- 10 Askeroglu U, Alleyne B, Guyuron B. Pharmaceutical and herbal products that may contribute to dry eyes. *Plast Reconstr Surg* 2013;131(1):159-167.
- 11 Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. *Eye (Lond)* 2022;36(2):361-368.
- 12 Perez VL, Stern ME, Pflugfelder SC. Inflammatory basis for dry eye disease flares. *Exp Eye Res* 2020;201:108294.
- 13 Hessen M, Akpek EK. Dry eye: an inflammatory ocular disease. J Ophthalmic Vis Res 2014;9(2):240-250.
- 14 Wolffsohn JS, Lingham G, Downie LE, *et al.* TFOS Lifestyle: impact of the digital environment on the ocular surface. *Ocul Surf* 2023;28:213-252.
- 15 McMonnies CW. Diagnosis and remediation of blink inefficiency. Cont Lens Anterior Eye 2021;44(3):101331.
- 16 Chidi-Egboka NC, Jalbert I, Wagner P, Golebiowski B. Blinking and

normal ocular surface in school-aged children and the effects of age and screen time. *Br J Ophthalmol* 2023;107(11):1613-1620.

- 17 Mohamed HB, Abd El-Hamid BN, Fathalla D, Fouad EA. Current trends in pharmaceutical treatment of dry eye disease: a review. *Eur J Pharm Sci* 2022;175:106206.
- 18 Paugh JR, Nguyen AL, Ketelson HA, Christensen MT, Meadows DL. Precorneal residence time of artificial tears measured in dry eye subjects. *Optom Vis Sci* 2008;85(8):725-731.
- 19 Mengher LS, Pandher KS, Bron AJ, Davey CC. Effect of sodium hyaluronate (0.1%) on break-up time (NIBUT) in patients with dry eyes. *Br J Ophthalmol* 1986;70(6):442-447.
- 20 Ang BCH, Sng JJ, Wang PXH, Htoon HM, Tong LHT. Sodium hyaluronate in the treatment of dry eye syndrome: a systematic review and meta-analysis. *Sci Rep* 2017;7(1):9013.
- 21 Calonge M, Sahyoun M, Baillif S, Gain P, Paw E, Mearza A, Cochener B. Sodium hyaluronate 0.30% ocular gel versus sodium hyaluronate 0.18% eye drop in the treatment of moderate to severe dry eye disease. *Eur J Ophthalmol* 2023;33(1):188-195.
- 22 Hong XF, Chen Y. Observation of clinical efficacy of different concentrations of sodium hyaluronate ophthalmic solution on dry eye after cataract surgery. *Zhejiang Clinical Medical Journal* 2016;18(10):1836-1837.
- 23 Jin HY, Dang JS. Clinical study on the recovery of tear film function after senile cataract surgery byhigh-concentrated sodium hyaluronate ophthalmic solution. *Huanan Guofang Yixue Zazhi (Mil Med J S Chin)* 2018;32(10):693-695.
- 24 Jun JH, Bang SP, Park HS, Yoon D, Ahn JY, Kim SJ, Kim HK. A randomized multicenter clinical evaluation of sequential application of 0.3% and 0.15% hyaluronic acid for treatment of dry eye. *Jpn J Ophthalmol* 2022;66(1):58-67.
- 25 Ntonti P, Panagiotopoulou EK, Karastatiras G, Breyannis N, Tsironi S, Labiris G. Impact of 0.1% sodium hyaluronate and 0.2% sodium hyaluronate artificial tears on postoperative discomfort following cataract extraction surgery: a comparative study. *Eye Vis (Lond)* 2019;6(1):1-9.
- 26 Song S. Observation on the clinical efficacy of different concentrations of sodium vitrate ophthalmic solution on dry eye after cataract surgery. *Special Health* 2018(15):64-65.
- 27 Yin YC, Kong L. Effects of mass fraction 0.1% and 0.3% sodium vitrate eye drops on dry tear film stability and visual quality after FS-LASIK. *Yangsheng Baojian Zhinan (Health Guide)* 2022;15:181-183.
- 28 Zheng XH, Zhao SZ. Effects of mass fraction 0.1% and 0.3% sodium vitrate eye drops on dry tear film stability and visual quality after FS-LASIK. *Zhonghua Shiyan Yanke Zazhi (Chin J Exp Ophthalmol)* 2018;36(5):373-379.
- 29 Jing CH. Analysis of clinical efficacy of different concentrations of sodium hyaluronate ophthalmic solution on dry eye after cataract surgery. *Yangsheng Baojian Zhinan (Health Guide)* 2019;17:33.
- 30 Yang XJ. Observation on the clinical efficacy of different concentrations of sodium vitrate ophthalmicsolution on dry eye after cataract surgery. *Yin Shi Bao Jian* 2019;6(10):58-59.

- 31 Cumpston MS, McKenzie JE, Welch VA, Brennan SE. Strengthening systematic reviews in public health: guidance in the Cochrane Handbook for Systematic Reviews of Interventions, 2nd edition. J Public Health (Oxf) 2022;44(4):e588-e592.
- 32 Tsubota K, Yokoi N, Watanabe H, *et al*. A new perspective on dry eye classification: proposal by the Asia dry eye society. *Eye Contact Lens* 2020;46(Suppl 1):S2-S13.
- 33 Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu ZG, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II definition and classification report. *Ocul Surf* 2017;15(3):276-283.
- 34 Yang YJ, Lee WY, Kim YJ, Hong YP. A meta-analysis of the efficacy of hyaluronic acid eye drops for the treatment of dry eye syndrome. *Int J Environ Res Public Health* 2021;18(5):2383.
- 35 You IC, Li Y, Jin R, Ahn M, Choi W, Yoon KC. Comparison of 0.1%, 0.18%, and 0.3% hyaluronic acid eye drops in the treatment of experimental dry eye. *J Ocul Pharmacol Ther* 2018;34(8):557-564.
- 36 Müller-Lierheim WGK. Why chain length of hyaluronan in eye drops matters. *Diagnostics (Basel)* 2020;10(8):E511.
- 37 Shimmura S, Ono M, Shinozaki K, Toda I, Takamura E, Mashima Y, Tsubota K. Sodium hyaluronate eyedrops in the treatment of dry eyes. *Br J Ophthalmol* 1995;79(11):1007-1011.
- 38 Wang X, Fan X, Wu Y, Mou Y, Min J, Jin X. Rear 4-min Schirmer test, a modified indicator of Schirmer test in diagnosing dry eye. *Sci Rep* 2022;12(1):6272.
- 39 Cho P, Yap M. Schirmer test. I. A review. Optom Vis Sci 1993;70(2): 152-156.
- 40 Tsubota K, Xu KP, Fujihara T, Katagiri S, Takeuchi T. Decreased reflex tearing is associated with lymphocytic infiltration in lacrimal glands. *J Rheumatol* 1996;23(2):313-320.
- 41 Tsubota K, Pflugfelder SC, Liu Z, *et al.* Defining dry eye from a clinical perspective. *Int J Mol Sci* 2020;21(23):9271.
- 42 Song JK, Lee K, Park HY, *et al.* Efficacy of carboxymethylcellulose and hyaluronate in dry eye disease: a systematic review and Meta-Analysis. *Korean J Fam Med* 2017;38(1):2-7.
- 43 Holly FJ, Lemp MA. Wettability and wetting of corneal epithelium. *Exp Eye Res* 1971;11(2):239-250.
- 44 Vanley GT, Leopold IH, Gregg TH. Interpretation of tear film breakup. Arch Ophthalmol 1977;95(3):445-448.

- 45 Yokoi N, Georgiev GA. Tear-film-oriented diagnosis for dry eye. *Jpn J Ophthalmol* 2019;63(2):127-136.
- 46 Nichols KK. Patient-reported symptoms in dry dye disease. Ocul Surf 2006;4(3):137-145.
- 47 Gomes JAP, Azar DT, Baudouin C, *et al.* TFOS DEWS II iatrogenic report. *Ocul Surf* 2017;15(3):511-538.
- 48 Stapleton F, Abad JC, Barabino S, Burnett A, et al. TFOS lifestyle: Impact of societal challenges on the ocular surface. Ocul Surf 2023;28:165-199.
- 49 Marinho A, Nunes C, Reis S. Hyaluronic acid: a key ingredient in the therapy of inflammation. *Biomolecules* 2021;11(10):1518.
- 50 Valachová K, Šoltés L. Hyaluronan as a prominent biomolecule with numerous applications in medicine. Int J Mol Sci 2021;22(13):7077.
- 51 Kotla NG, Bonam SR, Rasala S, Wankar J, Bohara RA, Bayry J, Rochev Y, Pandit A. Recent advances and prospects of hyaluronan as a multifunctional therapeutic system. *J Control Release* 2021;336: 598-620.
- 52 Zhang X, Wei D, Xu Y, Zhu Q. Hyaluronic acid in ocular drug delivery. *Carbohydr Polym* 2021;264:118006.
- 53 Brignole F, Pisella PJ, Dupas B, Baeyens V, Baudouin C. Efficacy and safety of 0.18% sodium hyaluronate in patients with moderate dry eye syndrome and superficial keratitis. *Graefes Arch Clin Exp Ophthalmol* 2005;243(6):531-538.
- 54 Guo YZ, Wang H. Sodium hyaluronate promotes proliferation, autophagy, and migration of corneal epithelial cells by downregulating miR-18a in the course of corneal epithelial injury. *Eur J Histochem* 2023;67(2):3663.
- 55 Moreno IY, Parsaie A, Gesteira TF, Coulson-Thomas VJ. Characterization of the limbal epithelial stem cell niche. *Invest Ophthalmol Vis Sci* 2023;64(13):48.
- 56 Abatangelo G, Vindigni V, Avruscio G, Pandis L, Brun P. Hyaluronic acid: redefining its role. *Cells* 2020;9(7):E1743.
- 57 Aragona P, Simmons PA, Wang H, Wang T. Physicochemical properties of hyaluronic acid-based lubricant eye drops. *Transl Vis Sci Technol* 2019;8(6):2.
- 58 Behrens A, Doyle JJ, Stern L, *et al.* Dysfunctional tear syndrome study group: dysfunctional tear syndrome: a delphi approach to treatment recommendations. *Cornea* 2006;25(8):900-907.